I also got out at ~$3--beyond a "short squeeze" is there any thing else that could be spiking interest--since the passing of Mr.Mann and the end of the Sanofi partnership has there been anything done by management to improve the outlook for MNKD and Afrezza? would really like to "screw" that jerk Adam Feurerstein who endlessly badmouthed Afeeza and the company
I'm very long on AVXL (back when it was $0.25 pre-split) but again this report is in "mice"-and the biotech universe is full of drugs that worked great in mice but not in humans-so although a positive result this still needs to be viewed with caution---I'm more excited by the patients in Australia who have requested to remain on the trial drug for a longer time because of the benefits they are seeing cognitively
The one thing that gets lost in all the hubris about the 3 patients that showed improvement in their ASIS scores (Patient #1, #3, #5) is that patient #2 (Jesi) although not showing an improvement in score did in fact show improvement in bladder and bowel function and this in itself is an incredible result-you simply can't underestimate the psychological/physical benefit that this is for anyone who is facing life in a wheelchair. I also believe patient #4's injuries must have been incredibly more traumatic for them not to have shown some benefit too
with so many potential "blockbusters"-including Kevetrin, bricilidin etc. why is this stock still languishing just above $1
this so called company has been "clinically dead" for years-Tighe (and his alias Ellen) and the rest of the pumpers have moved on to fleece other investors-why is this shell of a company allowed to be listed any longer???
Don't worry Adam Feurerstein (and his minion "Dr. Klein") will claim this is a placebo effect and that (as he was quoted in November 2015) "a cup of coffee" would work just as well.
Adam Feurerstein??? is that you?? or are you his little trained minion "Dr. Kline"--the "expert " he paraded out last November who has no university affliliation/no published papers in 5 years etc etc
What I see happening if the news is great (which I'm sure it will be) is that disgursting neandrathal Adam Feurerstein coming out with one of his "hit" pieces using his "trained seal" Dr. Kline to tear apart the data (just like he did last November)--maybe his pal Skrelli will also chime in too (but I think this slime ball has got other things to worry about right now)
any mention of patient #4 (I believe a T3 injury)-thoughts as to why no measurable improvement? (extent of injury-delay in implanting scaffold?)--although patient #2 (Jesi) didn't have a measurable ASIS improvement she has regained some bladder//bowel function which in of itself is remarkable-I really consider 4 of the 5 reported paitents to have improved beyond anything they would have without the scaffold-something I'm sure the FDA has taken note of as well
any word on why they felt patient #4 (I believe a T3 injury) didn't convert (but clearly no safety issue)--much more extensive injury? later implantation (delayed because patient had to be stabilized?-patient #2 (Jesi) was also unstable and had to stabilized before implantation yet she did recover some bladder and bowel function which in itself is remarkabale)---again thanks very much for the update
the Objective Performance Criterion (OPC) measure of study success for The INSPIRE Study is defined as 25% or more of the patients improving by at least one AIS grade by six months post-implantation.
so essentially 3 of the first 5 patients have done this (too early to determine if patient #6 will do so-but certainly strong likelihood they will)--that means that only 2 more conversions are needed to confirm "study success"--yea I would have to agree--"slam dunk"
also lost in all this is that patient #2 (Jesi) has also done well (although apparently no AIS grade improvement)-she has likely done far better than she would have without the scaffold--still believe she has likely met this criteria as well based on the many reports of her neurologic improvements
would like to hear what JN has to say about this news-he has written articles in the past stating where he thought the pps of In Vivo would go in the event of further positive results--well since that is now the case would very much like to hear what he thinks now
I'm sure one the bigger players (J&J/Stryker etc) are watching these results with very increased interest-I hope In Vivo management resists the possibility of a "buyout" and only entertains offers for a partnership--that way they can maintain control over the day to day activities of the company and still have more than enough money to continue the trial to its obvious successful conclusion leading up to licensing the scaffold (and then proceeding with the chronic spinal cord injury trial with stem cells)
I know that Dr. Langer (and some of the post doctorate fellows working in his lab) had published a paper about early studies using the polymer scaffold in retinal diseases (?retinitis pigmintosa)-I can't see why the scaffold couldn't be used in other applications (certainly knee osteoartritis is a huge opportunity if fibroblast stem cells could be implanted in the affected joint to make new cartilage)
you can be sure Immansdope is going to twist this into a negative----again as I've posted many times before-just leave him on "Ignore"-many of his most recent posts have centered on the lack of improvement in Patient #4/#5---now that that has been disproven--just ignore his histrionic nonsense once and for all
would just like some word on patient #4/#5---the first 3 patients have shown improvement (including improvement in ASIS scores in patient #1/#3---but patient #4 (implanted Aug 2015) and #5 (implanted Sept 2015) remain an "unknown" in all this---certainly they have shown "safety" (otherwise that would have been reported)-but its been ~7 months since the announcement of the scaffold insertion-hopefully next week at the conference this too will be updated
As I've said before don't feed this troll---all it does is embolden him to spew more of his nonsensical gibberish---this company is going forward in a very logical and strategically planned path--that's something Immansidope can't possible comprehend---just leave him on "Ignore" save your self the aggravation
This was the title of a "Seeking Alpha" article published in Aug 2013 by some hack named "Biotech Sage"--it was a disgusting "hit" piece designed to maximize his short position right around the time the former In Vivo CEO (Reynolds) was replaced--in this "article" he claimed NVIV wouldn't get any where near commercialization of the scaffold and even if it did it would take until 2019 and require 2-3 dilutions of the pps. I have continually asked him for a "rebuttal" based on how well the INSPIRE study is coming along--but to no avail
"NO PHARMA is going to leave that much money on the table"
I agree but I also believe no BIG pharma is going to sit idelly by and not put in a bid to buy out AVXL--I would expect a "bidding war" on taking over this company if the results continue to be exempliary (which I'm certain they will be--despite the nonsensical gibberish from that troll Adam Feurerstein and his trained seal "Dr. Kline")
I'm sick of all these less than worthless frivilous lawsuits---just a bunch of disgusting "ambulance chasers" trying to make a buck by fabricating charges that have no basis in fact--I think these clowns should have their licenses revoked for practising law